المؤلفون: Hu, B, Lin, X, Lee, HC, Huang, XL, Tidwell, RSS, Ahn, KW, Hu, ZH, Jabbour, E, Verstovsek, S, Ravandi, F, Garcia-Manero, G, Kharfan-Dabaja, MA, Hossain, NM, Marks, DI, Kamble, RT, Inamoto, Y, Kindwall-Keller, T, Saad, A, Litzow, MR, Savani, BN, Hale, GA, Bacher, U, Gerds, AT, Liesveld, JL, Ustun, C, Olsson, RF, Daly, A, Grunwald, MR, Solh, M, DeFilipp, Z, Aljurf, M, Wirk, B, Akpek, G, Nishihori, T, Cerny, J, Seo, S, Hsu, JW, Champlin, R, de Lima, M, Alyea, E, Popat, U, Sobecks, R, Scott, BL, Kantarjian, H, Cortes, J, Saber, W

المصدر: Leukemia & lymphoma. 61(12):2811-2820

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:144198286

المؤلفون: Aparicio AM; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Tidwell RSS; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas., Yadav SS; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas., Chen JS; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang M; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Liu J; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Guo S; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas., Pilié PG; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Yu Y; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas., Song X; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas., Vundavilli H; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Jindal S; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas., Zhu K; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Viscuse PV; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Lebenthal JM; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Hahn AW; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Soundararajan R; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Corn PG; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Zurita-Saavedra A; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Subudhi SK; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas., Wang W; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Huff C; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas., Troncoso P; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Allison JP; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas., Sharma P; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas., Logothetis CJ; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 01; Vol. 30 (13), pp. 2751-2763.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/mortality , Prostatic Neoplasms, Castration-Resistant*/genetics , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Prednisone*/administration & dosage , Prednisone*/therapeutic use , Abiraterone Acetate*/therapeutic use , Abiraterone Acetate*/administration & dosage, Humans ; Male ; Aged ; Middle Aged ; Thiohydantoins/administration & dosage ; Thiohydantoins/therapeutic use ; Thiohydantoins/adverse effects ; Aged, 80 and over ; Androgen Antagonists/therapeutic use ; Carboplatin/administration & dosage ; Carboplatin/therapeutic use ; Ipilimumab/administration & dosage ; Ipilimumab/therapeutic use ; Taxoids

المؤلفون: Lachowiez CA; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Loghavi S; The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas., Zeng Z; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Tanaka T; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Kim YJ; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Uryu H; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Turkalj S; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.; Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom., Jakobsen NA; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.; Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom., Luskin MR; Dana-Farber Cancer Institute, Leukemia Program, Boston, Massachusetts., Duose DY; The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, Houston, Texas., Tidwell RSS; The University of Texas MD Anderson Cancer Center, Department of Biostatistics, Houston, Texas., Short NJ; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Borthakur G; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Kadia TM; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Masarova L; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Tippett GD; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Bose P; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Jabbour EJ; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Ravandi F; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Daver NG; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Garcia-Manero G; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Kantarjian H; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Garcia JS; Dana-Farber Cancer Institute, Leukemia Program, Boston, Massachusetts., Vyas P; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.; Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom., Takahashi K; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., Konopleva M; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas., DiNardo CD; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.

المصدر: Blood cancer discovery [Blood Cancer Discov] 2023 Jul 05; Vol. 4 (4), pp. 276-293.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101764786 Publication Model: Print Cited Medium: Internet ISSN: 2643-3249 (Electronic) Linking ISSN: 26433230 NLM ISO Abbreviation: Blood Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasm Recurrence, Local*/chemically induced , Antineoplastic Agents*/adverse effects, Humans ; Azacitidine/adverse effects ; Isocitrate Dehydrogenase/genetics

المؤلفون: Siddiqui BA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chapin BF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jindal S; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Duan F; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Basu S; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yadav SS; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gu AD; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Espejo AB; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kinder M; Janssen Research & Development, Spring House, Pennsylvania, USA., Pettaway CA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ward JF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Troncoso P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Corn PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Logothetis CJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Knoblauch R; Janssen Research & Development, Spring House, Pennsylvania, USA., Hutnick N; Janssen Research & Development, Spring House, Pennsylvania, USA., Gottardis M; Janssen Research & Development, Spring House, Pennsylvania, USA., Drake CG; Janssen Research & Development, Spring House, Pennsylvania, USA.; Department of Medicine, Columbia University Medical Center, New York, New York, USA.; Department of Urology, Columbia University Medical Center, New York, New York, USA., Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA SKSubudhi@mdanderson.org padsharma@mdanderson.org.; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA SKSubudhi@mdanderson.org padsharma@mdanderson.org.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Mar; Vol. 11 (3).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/pathology, Male ; Humans ; Leukocytes, Mononuclear/pathology ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Immunosuppressive Agents ; Tumor Microenvironment

المؤلفون: Newhook TE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Vreeland TJ; Department of Surgery, Brooke Army Medical Center, San Antonio, TX., Griffin JF; Piedmont Physicians Athens Surgical Oncology, Athens, GA., Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Prakash LR; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Koay EJ; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ludmir EB; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Smaglo BG; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Pant S; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Overman M; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wolff RA; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ikoma N; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Maxwell J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Kim MP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Katz MHG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tzeng CD; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: Annals of surgery [Ann Surg] 2023 Mar 01; Vol. 277 (3), pp. 484-490. Date of Electronic Publication: 2022 Dec 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE

مواضيع طبية MeSH: Pancreatic Neoplasms*/surgery , Adenocarcinoma*/surgery , Carcinoma, Pancreatic Ductal*/surgery, Humans ; CA-19-9 Antigen ; Neoadjuvant Therapy ; Retrospective Studies ; Prognosis

المؤلفون: Soundararajan R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Viscuse P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Pilie P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Liu J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA., Logotheti S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Laberiano Fernández C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lorenzini D; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Instituto Nazionale dei Tumori, 20133 Milan, Italy., Hoang A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lu W; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Soto LMS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Xu M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA., Shepherd PDA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Navone NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA., Lozano G; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Logothetis C; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA., Long JP; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA., Estecio MR; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Tzelepi V; Department of Pathology, University of Patras, 26504 Patras, Greece., Aparicio AM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

المصدر: Cancers [Cancers (Basel)] 2022 Jun 30; Vol. 14 (13). Date of Electronic Publication: 2022 Jun 30.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Arun BK; Department of Breast Medical Oncology and Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Peterson SK; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sweeney LE; Houston Breast Screening Network, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bluebond RD; Department of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Makhnoon S; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kushwaha AC; Houston Breast Screening Network, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Cancer [Cancer] 2022 Jan 01; Vol. 128 (1), pp. 94-102. Date of Electronic Publication: 2021 Aug 23.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/diagnostic imaging , Breast Neoplasms*/genetics , Hereditary Breast and Ovarian Cancer Syndrome*/diagnosis , Hereditary Breast and Ovarian Cancer Syndrome*/genetics , Ovarian Neoplasms*/diagnostic imaging , Ovarian Neoplasms*/genetics, Female ; Genes, BRCA2 ; Genetic Counseling ; Genetic Predisposition to Disease ; Genetic Testing ; Humans ; Mutation ; Referral and Consultation

المؤلفون: Tidwell RSS; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX., Thall PF; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX., Yuan Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: JCO precision oncology [JCO Precis Oncol] 2021 Nov 10; Vol. 5. Date of Electronic Publication: 2021 Nov 10 (Print Publication: 2021).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: eCollection Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol

مواضيع طبية MeSH: Bayes Theorem* , Dose-Response Relationship, Drug*, Pancreatic Neoplasms/*drug therapy, Humans ; Treatment Outcome

المؤلفون: Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Siddiqui BA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Aparicio AM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yadav SS; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Basu S; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chen H; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jindal S; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Varma A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Logothetis CJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Allison JP; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Corn PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA padsharma@mdanderson.org.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Oct; Vol. 9 (10).

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , CTLA-4 Antigen/*therapeutic use , Immune Checkpoint Inhibitors/*therapeutic use , Neutrophils/*metabolism , Prostatic Neoplasms, Castration-Resistant/*drug therapy, Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Male ; Middle Aged ; Pilot Projects ; Tumor Microenvironment

المؤلفون: Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tkadia@mdanderson.org., Reville PK; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kornblau S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dinardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Islam R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

المصدر: The Lancet. Haematology [Lancet Haematol] 2021 Aug; Vol. 8 (8), pp. e552-e561.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Leukemia, Myeloid, Acute/*drug therapy , Myelodysplastic Syndromes/*drug therapy, Adolescent ; Adult ; Aged ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Cladribine/administration & dosage ; Cohort Studies ; Cytarabine/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Idarubicin/administration & dosage ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Myelodysplastic Syndromes/pathology ; Prognosis ; Remission Induction ; Risk Factors ; Sulfonamides/administration & dosage ; Young Adult